Abstract
EMT in immuno-resistance.
Highlights
The advent of new immunotherapy approaches has improved survival for many patients with advanced malignancies, the high degree of nonresponders, especially in highly prevalent malignancies including breast, colon and prostate cancers was a strong reminder that we possess only partial understanding of the events underlying the immune resistance of tumors
Activation of epithelial mesenchymal transition (EMT) programs in carcinoma cells can provide them with stem cell properties and as well, they should be considered as a potential source of cancer stem cells (CSCs) [2]
Exploiting the human mammary carcinoma model MCF7, we provided evidence indicating that MCF7 cells that experienced EMT after stable expression of SNAIL1, or after prolonged exposure to TNF-α exhibited reduced susceptibility to cytotoxic T-lymphocytes (CTL)-mediated lysis [3]
Summary
The advent of new immunotherapy approaches has improved survival for many patients with advanced malignancies, the high degree of nonresponders, especially in highly prevalent malignancies including breast, colon and prostate cancers was a strong reminder that we possess only partial understanding of the events underlying the immune resistance of tumors. Epithelial mesenchymal transition (EMT) is an effective strategy by which cancer cells could gain plasticity. At least a fraction of cancer cells can activate this process in response to various stimuli while they may acquire in addition a drug resistant phenotype and an increased ability to invade which is a prerequisite for entry into the circulation (as Circulating Tumor Cells) and metastatic dissemination [1].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
